A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys

This preclinical study investigated Adipotide, a peptidomimetic designed to selectively target the vasculature of white adipose tissue. The research used obese rhesus monkeys as a model, a significant choice given their physiological proximity to humans. The peptide was administered subcutaneously daily for 28 days, with continuous monitoring of weight, body composition, and metabolic parameters.

Adipotide's mechanism of action is based on binding to the prohibitin receptor on the surface of blood vessels supplying white adipose tissue. By inducing targeted apoptosis in these endothelial cells, the peptide effectively cuts off the blood supply to fat tissue, leading to its reabsorption. MRI and dual-energy X-ray absorptiometry (DEXA) confirmed the selective fat reduction.

The results were striking: treated monkeys showed an average weight loss of 10.6% in just 28 days, accompanied by significant improvement in insulin resistance. Body composition analyzed by DEXA showed preferential reduction of fat mass while relatively preserving lean mass. There was also improvement in the overall metabolic profile of the animals.

A notable aspect was the observation of transient renal side effects, which reversed after treatment discontinuation. The study represented an innovative proof of concept for the "vascular starvation" approach to adipose tissue as an anti-obesity strategy, paving the way for a new therapeutic class based on targeted peptides.